BIIB vs BLUE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and BLUE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileBLUE’s FA Score has 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- BLUE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while BLUE’s TA Score has 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 6 bearish.
- BLUE’s TA Score: 3 bullish, 6 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +0.19% price change this week, while BLUE (@Biotechnology) price change was +0.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.20%. For the same industry, the average monthly price growth was -1.54%, and the average quarterly price growth was -7.79%.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
BLUE is expected to report earnings on Feb 25, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+3.20% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+8.19% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | BLUE | BIIB / BLUE | |
| Capitalization | 31.3B | 40.7M | 76,904% |
| EBITDA | 2.04B | -215.81M | -944% |
| Gain YTD | -22.286 | -50.120 | 44% |
| P/E Ratio | 26.95 | N/A | - |
| Revenue | 9.84B | 53.1M | 18,524% |
| Total Cash | 1.05B | 70.7M | 1,485% |
| Total Debt | 7.34B | 368M | 1,994% |
BIIB | BLUE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 67 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 65 | |
P/E GROWTH RATING 1..100 | 96 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BLUE's Valuation (24) in the Biotechnology industry is significantly better than the same rating for BIIB (93). This means that BLUE’s stock grew significantly faster than BIIB’s over the last 12 months.
BLUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100). This means that BLUE’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as BLUE (98). This means that BIIB’s stock grew similarly to BLUE’s over the last 12 months.
BIIB's Price Growth Rating (65) in the Biotechnology industry is in the same range as BLUE (65). This means that BIIB’s stock grew similarly to BLUE’s over the last 12 months.
BIIB's P/E Growth Rating (96) in the Biotechnology industry is in the same range as BLUE (100). This means that BIIB’s stock grew similarly to BLUE’s over the last 12 months.
| BIIB | BLUE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 79% |
| Advances ODDS (%) | 12 days ago 54% | 17 days ago 78% |
| Declines ODDS (%) | 10 days ago 69% | 5 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 46% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 64% | N/A |
